Bone Fractures News
-
GlaxoSmithKline Plc and Theravance Inc. won U.S. approval of their once-daily drug Breo Ellipta to treat a lung disorder that is the third-leading cause of death.
-
U.S. hospitals are charging prices that can be thousands of dollars different for the same medical procedures, even within the same towns, according to federal data released today.
-
AstraZeneca Plc’s Nexium, Pfizer Inc.’s Protonix and Takeda Pharmaceutical Co.’s Prevacid, ulcer drugs also prescribed for indigestion, were linked to a higher risk of bone fractures in older women and to a diarrhea-causing infection, two studies found.
-
AstraZeneca Plc’s Nexium, Pfizer Inc.’s Protonix and Takeda Pharmaceutical Co.’s Prevacid may raise the risk of bone fractures when taken in high doses or for a year or more, U.S. regulators said.
-
Johnson & Johnson, which is fighting more than 10,000 lawsuits over its recalled hip implants, is negotiating a potential settlement with patients that may eventually total more than $2 billion, according to five people familiar with the matter.
-
A salmon hormone used to treat post- menopausal osteoporosis may not reduce bone fractures enough to outweigh the drug’s cancer risks, U.S. regulators said.
-
Andrew Ekdahl, the president of Johnson & Johnson’s DePuy unit, told jurors the company recalled 93,000 all-metal hip implants because they “did not meet the clinical needs for the product” and not because they were unsafe.
-
Johnson & Johnson’s DePuy unit president told a California surgeon months before 93,000 metal hip implants were recalled that sales would be halted, without explaining that the devices were increasingly failing, the doctor testified.
-
A bioengineer at Johnson & Johnson’s DePuy unit testified that he spent three years studying a redesign of metal-on-metal hip devices that the company recalled in 2010 because of their failure rate.
-
The lead surgeon-designer for Johnson & Johnson’s recalled metal-on-metal hip implants testified that he wouldn’t have sold the device if he knew it would have a failure rate of 20 percent or more.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page